UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate®

Evaluation and diagnosis of the patient with renal allograft dysfunction

Authors
Pradeep V Kadambi, MD, MBA
Daniel C Brennan, MD, FACP
W James Chon, MD, FACP
Section Editor
Barbara Murphy, MB, BAO, BCh, FRCPI
Deputy Editor
Albert Q Lam, MD

INTRODUCTION

The most common complication of renal transplantation is allograft dysfunction, which in some cases leads to graft loss. Although there is a wide intercenter variability, data from the United States indicate that overall one-year unadjusted survival of a renal allograft is approximately 89 percent for a deceased-donor kidney and approximately 95 percent for a living-donor kidney [1]. Prompt recognition and evaluation of allograft dysfunction is vital, as it is usually reversible. Persistent dysfunction without timely intervention may lead to irreversible loss of allograft function and, eventually, allograft failure.

A number of risk factors have been identified for lower one-year deceased-donor renal allograft survival. These include prior sensitization with >50 percent panel reactivity, the presence of delayed graft function (DGF; defined as the requirement for dialysis during the first week after transplantation), the number and severity of rejection episodes, second or third transplant, donor age <5 or >60 years, greater degrees of human leukocyte antigen (HLA) mismatching, and allograft dysfunction at discharge (plasma creatinine concentration >2 mg/dL [176 micromol/L]).

The causes of renal allograft dysfunction vary with the time (usually classified as immediate, early, and late period) after transplantation.

This topic will provide an overview of the evaluation and diagnosis of renal allograft dysfunction among patients who have undergone kidney transplantation. The classification, diagnosis, and treatment of acute renal allograft rejection, chronic renal allograft nephropathy, and BK virus-induced (polyomavirus-induced) nephropathy are discussed in more detail elsewhere. (See "Clinical manifestations and diagnosis of acute renal allograft rejection" and "Acute renal allograft rejection: Treatment" and "C4d staining in renal allografts and treatment of antibody-mediated rejection" and "Chronic renal allograft nephropathy" and "Clinical manifestations and diagnosis of BK virus-induced (polyomavirus-induced) nephropathy in kidney transplantation" and "Prevention and management of BK virus-induced (polyomavirus-induced) nephropathy in kidney transplantation".)

DEFINITIONS

There is no consensus definition for allograft dysfunction following kidney transplant. We define acute renal allograft dysfunction as one or more of the following:

                               

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Jul 2017. | This topic last updated: May 16, 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
References
Top
  1. http://optn.transplant.hrsa.gov/ (Accessed on November 20, 2013).
  2. Saidi RF, Elias N, Kawai T, et al. Outcome of kidney transplantation using expanded criteria donors and donation after cardiac death kidneys: realities and costs. Am J Transplant 2007; 7:2769.
  3. Chapman JR, O'Connell PJ, Nankivell BJ. Chronic renal allograft dysfunction. J Am Soc Nephrol 2005; 16:3015.
  4. D'Cunha PT, Parasuraman R, Venkat KK. Rapid resolution of proteinuria of native kidney origin following live donor renal transplantation. Am J Transplant 2005; 5:351.
  5. Myslak M, Amer H, Morales P, et al. Interpreting post-transplant proteinuria in patients with proteinuria pre-transplant. Am J Transplant 2006; 6:1660.
  6. Amer H, Fidler ME, Myslak M, et al. Proteinuria after kidney transplantation, relationship to allograft histology and survival. Am J Transplant 2007; 7:2748.
  7. Knoll GA. Proteinuria in kidney transplant recipients: prevalence, prognosis, and evidence-based management. Am J Kidney Dis 2009; 54:1131.
  8. Tsampalieros A, Knoll GA. Evaluation and Management of Proteinuria After Kidney Transplantation. Transplantation 2015; 99:2049.
  9. Cravedi P, Codreanu I, Satta A, et al. Cyclosporine prolongs delayed graft function in kidney transplantation: are rabbit anti-human thymocyte globulins the answer? Nephron Clin Pract 2005; 101:c65.
  10. Lechevallier E, Dussol B, Luccioni A, et al. Posttransplantation acute tubular necrosis: risk factors and implications for graft survival. Am J Kidney Dis 1998; 32:984.
  11. Bleyer AJ, Burkart JM, Russell GB, Adams PL. Dialysis modality and delayed graft function after cadaveric renal transplantation. J Am Soc Nephrol 1999; 10:154.
  12. Nogueira JM, Cangro CB, Fink JC, et al. A comparison of recipient renal outcomes with laparoscopic versus open live donor nephrectomy. Transplantation 1999; 67:722.
  13. Van Biesen W, Vanholder R, Van Loo A, et al. Peritoneal dialysis favorably influences early graft function after renal transplantation compared to hemodialysis. Transplantation 2000; 69:508.
  14. Torregrosa JV, Campistol JM, Fenollosa B, et al. Role of secondary hyperparathyroidism in the development of post-transplant acute tubular necrosis. Nephron 1996; 73:67.
  15. Lind MY, Zur Borg IM, Hazebroek EJ, et al. The effect of laparoscopic and open donor nephrectomy on the long-term renal function in donor and recipient: a retrospective study. Transplantation 2005; 80:700.
  16. Moers C, Smits JM, Maathuis MH, et al. Machine perfusion or cold storage in deceased-donor kidney transplantation. N Engl J Med 2009; 360:7.
  17. Schnuelle P, Gottmann U, Hoeger S, et al. Effects of donor pretreatment with dopamine on graft function after kidney transplantation: a randomized controlled trial. JAMA 2009; 302:1067.
  18. Montgomery RA, Hardy MA, Jordan SC, et al. Consensus opinion from the antibody working group on the diagnosis, reporting, and risk assessment for antibody-mediated rejection and desensitization protocols. Transplantation 2004; 78:181.
  19. Kujovich JL. Thrombophilia and thrombotic problems in renal transplant patients. Transplantation 2004; 77:959.
  20. Pérez Fontán M, Rodríguez-Carmona A, García Falcón T, et al. Peritoneal dialysis is not a risk factor for primary vascular graft thrombosis after renal transplantation. Perit Dial Int 1998; 18:311.
  21. Ojo AO, Hanson JA, Wolfe RA, et al. Dialysis modality and the risk of allograft thrombosis in adult renal transplant recipients. Kidney Int 1999; 55:1952.
  22. Humar A, Matas AJ. Surgical complications after kidney transplantation. Semin Dial 2005; 18:505.
  23. Bakir N, Sluiter WJ, Ploeg RJ, et al. Primary renal graft thrombosis. Nephrol Dial Transplant 1996; 11:140.
  24. Irish A. Renal allograft thrombosis: can thrombophilia explain the inexplicable? Nephrol Dial Transplant 1999; 14:2297.
  25. Oh J, Schaefer F, Veldmann A, et al. Heterozygous prothrombin gene mutation: a new risk factor for early renal allograft thrombosis. Transplantation 1999; 68:575.
  26. Wüthrich RP, Cicvara-Muzar S, Booy C, Maly FE. Heterozygosity for the factor V Leiden (G1691A) mutation predisposes renal transplant recipients to thrombotic complications and graft loss. Transplantation 2001; 72:549.
  27. Robertson AJ, Nargund V, Gray DW, Morris PJ. Low dose aspirin as prophylaxis against renal-vein thrombosis in renal-transplant recipients. Nephrol Dial Transplant 2000; 15:1865.
  28. Kusyk T, Verran D, Stewart G, et al. Increased risk of hemorrhagic complications in renal allograft recipients receiving systemic heparin early posttransplantation. Transplant Proc 2005; 37:1026.
  29. Lucewicz A, Wong G, Lam VW, et al. Management of primary symptomatic lymphocele after kidney transplantation: a systematic review. Transplantation 2011; 92:663.
  30. Makiyama K, Tanabe K, Ishida H, et al. Successful renovascular reconstruction for renal allografts with multiple renal arteries. Transplantation 2003; 75:828.
  31. Bolander JE 2nd, Carter CB. Cholesterol embolization in renal allografts. J Am Soc Nephrol 1996; 7:18.
  32. Ripple MG, Charney D, Nadasdy T. Cholesterol embolization in renal allografts. Transplantation 2000; 69:2221.
  33. Sewpaul A, Sayer JA, Mohamed MA, et al. Rapid onset intratubular calcification following renal transplantation requiring urgent parathyroidectomy. Clin Nephrol 2007; 68:47.
  34. Tarplin S, Ganesan V, Monga M. Stone formation and management after bariatric surgery. Nat Rev Urol 2015; 12:263.
  35. Andersson H, Bosaeus I, Fasth S, et al. Cholelithiasis and urolithiasis in Crohn's disease. Scand J Gastroenterol 1987; 22:253.
  36. Lefaucheur C, Nochy D, Amrein C, et al. Renal histopathological lesions after lung transplantation in patients with cystic fibrosis. Am J Transplant 2008; 8:1901.
  37. Lieske JC, Regnier C, Dillon JJ. Use of sevelamer hydrochloride as an oxalate binder. J Urol 2008; 179:1407.
  38. Caravaca F, Ruiz AB, Escola JM, et al. [Either calcium carbonate or sevelamer decreases urinary oxalate excretion in chronic renal failure patients]. Nefrologia 2007; 27:466.
  39. Tang X, Voskoboev NV, Wannarka SL, et al. Oxalate quantification in hemodialysate to assess dialysis adequacy for primary hyperoxaluria. Am J Nephrol 2014; 39:376.
  40. Watts RW, Veall N, Purkiss P. Oxalate dynamics and removal rates during haemodialysis and peritoneal dialysis in patients with primary hyperoxaluria and severe renal failure. Clin Sci (Lond) 1984; 66:591.
  41. Ramos EL. Recurrent diseases in the renal allograft. J Am Soc Nephrol 1991; 2:109.
  42. Chadban S. Glomerulonephritis recurrence in the renal graft. J Am Soc Nephrol 2001; 12:394.
  43. Varma MC, Kushner YB, Ko DS, et al. Early onset adenovirus infection after simultaneous kidney-pancreas transplant. Am J Transplant 2011; 11:623.
  44. Storsley L, Gibson IW. Adenovirus interstitial nephritis and rejection in an allograft. J Am Soc Nephrol 2011; 22:1423.
  45. Ponticelli C, Moroni G, Glassock RJ. De novo glomerular diseases after renal transplantation. Clin J Am Soc Nephrol 2014; 9:1479.
  46. Wilson CH, Rix DA, Manas DM. Routine intraoperative ureteric stenting for kidney transplant recipients. Cochrane Database Syst Rev 2013; :CD004925.
  47. Brennan DC, Agha I, Bohl DL, et al. Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction. Am J Transplant 2005; 5:582.
  48. Jolly EC, Adshead JM, Farrington K. The retained stent: forgotten but not gone. Kidney Int 2010; 77:260.
  49. Schwarz A, Hiss M, Gwinner W, et al. Course and relevance of arteriovenous fistulas after renal transplant biopsies. Am J Transplant 2008; 8:826.